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Abstract
Background: For the surgical treatment of recurrent primary spontaneous pneumothoraces (rPSP) different
operative therapies are applied to achieve permanent freedom from recurrence.
Methods/design: This multicenter clinical trial evaluates the long-term results of two commonly applied surgical
techniques for the treatment of rPSP. Based on the inclusion and exclusion criteria, and after obtaining the patients’
informed consent, participants are randomized into the two surgical treatment arms: pulmonary wedge resection
plus parietal pleurectomy (WRPP) or parietal pleurectomy alone (PP). Consecutively, all study participants will be
followed up for two years to evaluate the surgical long-term effect. The primary efficacy endpoint is the recurrence
rate of pneumothorax within 24 months after surgery. The calculated sample size is 360 patients (n = 180 per
treatment arm) to prove superiority of one of the two treatments. So far, 22 surgical sites have submitted their
declaration of commitment, giving the estimated number of participating patients.
Discussion: A prospective randomized clinical trial has been started to compare two established surgical therapies
to evaluate the long-term results regarding recurrence rates. Furthermore, cost of treatment, and influence on the
perioperative morbidity and mortality as well as on quality of life are analyzed. If the study reveals equivalence for
both surgical techniques, unnecessary pulmonary resections could be avoided.
Trial registration: ClinicalTrials gov: NCT01855464, 06.05 2013.
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A pneumothorax (PTX) is an accumulation of air in the
pleural space between the lung and chest wall [1]:
A primary pneumothorax (pPTX) occurs in healthy
individuals without pre-existing lung disease and with-
out previous thoracic intervention or chest injury.
A secondary pneumothorax is usually the result of
an underlying lung disease (for example, pulmonary
emphysema) or a previous intervention (such as pleural
puncture) or a thoracic trauma (both blunt and
penetrating).
pPTX represents a common disease in industrialized
countries with an annual incidence of 18–28 per 100,000
[2, 3]. The goal of surgical pneumothorax treatment is
full re-expansion of the collapsed lung parenchyma and
recurrence prevention. Varying surgical strategies are
followed to achieve these targets. Thoracoscopic parietal
pleurectomy is the most frequently used surgical tech-
nique. The benefit of additional resection of the pulmon-
ary apex, however, is still questionable [4, 5]. A theoretical
advantage might be a stronger adhesion between the
stapled apex of the lung and the chest wall (for example,
in the sense of a foreign body reaction), which could be
accompanied by a lower recurrence rate. On the other
hand, the use of stapling devices for pulmonary wedge
resection increases surgical costs and the risk of postoper-
ative bleeding and parenchymal fistulas, translating into
longer hospital stays. However, both surgical strategies are
routinely applied in Germany’s specialized thoracic sur-
gery units. While their published short-term postoperative
results seem to be comparable, long-term results are still
missing. Furthermore, the associated perioperative mor-
bidity and mortality and the postoperative quality of life
have not been evaluated so far. In a recent observational
study, it has been shown that up to 45 % of patients after
operative therapy have recurrent and occasionally per-
sistent postoperative symptoms such as scar pain and
paresthesia [6]. Until now there has been no prospective
randomized clinical trial on this topic. Retrospective co-
hort analyses describe both methods as equivalent [7].
The rationale of the study protocol for this prospective
randomized multicenter study was to evaluate whether
pulmonary wedge resection in combination with a partial
apical pleurectomy (WRPP) is superior to the partial




The WOPP (Wedge Resection or Parietal Pleurectomy
for the Treatment of Recurrent Pneumothorax) study is
a two-arm, prospective, randomized, nationwide multicen-
ter clinical study in thoracic surgery, which was designed
to test the hypothesis of whether partial pleurectomy for
the treatment of recurrent primary pneumothorax alone is
inferior compared to an additional wedge resection re-
garding the recurrence rate over two years.
Inclusion and exclusion criteria
All patients between 15 and 40 years of age with recurrent
pPTX and patients who have a therapy refractory first
event of a pneumothorax are included. A treatment-
resistant first event of a pneumothorax is considered to be
a pPTX treated by insertion of a chest tube and PTX
recurrence following chest tube removal during the same
hospital stay. Excluded are patients with existing pulmon-
ary fistula, patients with known underlying lung disease,
and patients who have already undergone surgical or
interventional pleurodesis or ipsilateral thoracic surgery.
The latter does not include previously inserted chest
tubes. The presence of single or multiple small or large
bullae in the preoperative imaging or during thoracoscopy
does not represent an exclusion criterion for patients.
Ethical approval statement
The ethics committees of the University of Würzburg
and all participating centers have approved the study
protocol. A list of all ethical bodies that approved this
study is provided in Additional file 1.
Randomization
To prevent selection bias and insure against accidental
bias, we will allocate patients to the treatment groups by
randomization. In this way we can expect to get compar-
able study groups regarding observed and unobserved
confounders.
Patients who are suitable after verification of the inclu-
sion and exclusion criteria will be thoroughly informed
about the WOPP study by a study physician. After
approval of the study and submission of the written
informed consent, patients are randomized. Randomization
is done electronically via a web-based software tool (Secu-
Trial, interActive Systems GmbH, Berlin, Germany). We
chose an allocation ratio of 1:1 because it maximizes statis-
tical power for a given total sample size and there are no
ethical or practical objections to this ratio. To minimize
random error, 750 patients are to be screened and 360
patients (n = 180 per arm) will be randomized. Twenty
centers have declared their participation in the study. The
study design is shown in Fig. 1.
Blinding
Blinding of the patient and the surgeon after randomization
is not meaningful because staple lines after pulmonary
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wedge resection can often be seen on postoperative
chest X-rays.
Endpoints
The primary endpoint is PTX recurrence within the first
24 months after operative treatment. PTX recurrence is
defined as postoperative lung collapse documented by
chest X-ray. Secondary endpoints are morbidity, mortal-
ity, and postoperative convalescence. Morbidity will be
differentiated between general and surgical complications.
In addition, postoperative pain (at rest/under exertion)
will be determined by the visual analogue scale (VAS).
Postoperative quality of life will be captured by using the
SF-36 questionnaire.
Sample size estimation
The sample size calculation is based on the primary
endpoint PTX recurrence within the first 24 months.
We will test the null hypothesis of equal underlying
population proportions for PTX recurrence for patients
treated with pPTX alone and patients treated by WRPP
by using a two-sided Fisher’s exact test at significance
level 0.05.
Our assumptions for calculating the sample size are
based on Czerny et al. [7]. Conservatively we assume
underlying PTX recurrence proportions of 8.6 % for
patients under pPTX and 1.4 % for patients under
WRPP, a difference of 7.2 %. Sample sizes of 170 for
both groups ensure a power of 80 % to detect this dif-
ference as a significant deviation from the null hypoth-
esis of equal PTX recurrence proportions for both
treatment strategies. Due to the visits without painful
procedures and the comparatively young and healthy
study population, we assume a low drop-out rate of
5 %. Therefore, 2*180 = 360 patients are to be included
in the study at the beginning. PASS 11, developed by
NCSS Statistical Software, Kaysville, UT, USA, was used
for sample size calculation.
Fig. 1 Course of the WOPP trial
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Statistical analysis
The primary statistical analysis will be performed in the
intention-to-treat (ITT) population. This analysis set
includes all randomized subjects for which a diagnostic
thoracoscopy has confirmed that thoracoscopic oper-
ation is feasible. We assume that the number of patients
with recurrent pneumothorax after 24 months follows a
binomial distribution in both groups. Within the pri-
mary analysis we will test the null hypothesis of equal
proportions, which means equal probabilities for recur-
rent pneumothorax after 24 months for patients subject
to WRPP and patients subject to PP by a two-sided
Fisher’s exact test. Furthermore, a stratified analysis with
the stratification factor study center will be performed
using Mantel-Haenszel estimation of relative risk and
testing for heterogeneity of stratum risks.
Within a secondary analysis we will calculate an ad-
justed odds ratio for the experimental treatment method
WRPP relative to the comparing treatment PP using
multiple logistic regression analysis. Secondary outcome
analyses will be carried out depending on scale level and
distribution and will be considered exploratory. In our
analyses, 95 % confidence intervals will be calculated.
The method for constructing the confidence interval in
each case will depend on the type of the response
variable and the variable to be tested. Controlling for
potential confounders (such as age, gender, and smok-
ing) will be performed by using multiple statistical
models adjusting for these variables. Additional subgroup
analyses considering gender aspects, age, and study center
are planned. SAS 9.3 or corresponding subsequent SAS
versions will be used for all data analyses.
Study procedure
All patients with pPTX recurrence or a refractory first
event will be screened for study participation. For each
potential study participant the inclusion and exclusion
criteria will be checked by a study physician. After pro-
viding informed consent, the participant will be random-
ized in one study group.
The baseline pain level and the quality of life are
determined using the SF-36 questionnaire and the VAS
score prior to any other study intervention in all partici-
pants. The standard treatment is parietal pleurectomy
alone (control arm), and the validating therapy is the
parietal pleurectomy in combination with an additional
apical pulmonary wedge resection (experimental arm).
All surgeries are performed by video-assisted thoraco-
scopy under general anesthesia and include a parietal
pleurectomy for PTX treatment. Additionally, in the
experimental group an apical pulmonary wedge resection
is performed. The postoperative treatment is carried out
according to the respective hospital standard. Periopera-
tive variables like morbidity, mortality, subjective pain,
duration of chest tube, surgical reintervention, and length
of hospital stay will be determined. To assess the long-
term effect of surgical intervention, all patients will be
followed up for two years. The examinations for the indi-
vidual follow-up visits are listed in Table 1.
Table 1 Overview of the study-related examinations
Pre-OP Intra-OP Station Follow-up
Visit V1 V2 V3 V4 V5





Smoking X X X X X
Physical examination X
Chest X-raya X
Pain level (VAS) X X X X X
Quality of life (SF-36, German version) X X X X X
Vanderschueren classification X
Postoperative complications X X
AEs/SAEs X X X X
Duration of hospital stay X X
Material costsb X
aIn case of pregnancy of a study participant, the chest X-ray will be replaced by a chest ultrasound
bAt the end of the operation, the number of used trocars and stapling magazines will be documented
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Data management
The patient data are collected using electronic data entry
screens (Case Report Forms, eCRFs). The study software
complies with the regulatory requirements in accordance
with GCP, FDA 21 CFR Part 11, and contains i) audit
trail, ii) electronic signature, iii) programmable plausibil-
ity, consistency, and range checks, iv) query manage-
ment system for online monitoring, and v) customizable
roles and permissions system. In the study, software
pseudonyms for the study data are used. This ensures
the strict separation of identifying data (IDAT) and
medical data (MDAT) of patients. Medical data are sent
without personally identifiable information to the study
database and saved there. However, any identifying
patient data will be printed at the study center and
remain there. The link between IDAT and MDAT can
only be carried out by using a key, also called the
pseudonym. Each study center maintains a confidential
list of all patients, in which the patient numbers are
connected with the full patient names. Only the local
study team and the monitor will have access to this list.
The original files can be viewed by monitors, auditors,
and inspectors. The study database is protected by an
authentication method. Only authorized study personnel
with a personal identifier code will have access to the
study database. Individual permission levels and roles
are defined. This affords the implementation of different
processing modalities of the study data, for example, to
unlock certain forms (partial data) for editing, reading,
or data control (review). The study database is perman-
ently accessible via the Internet. The study data are
recorded online and are transmitted directly into the
study database; there is no local data storage. Data trans-
fer between the local computer and the study database
occurs via a secure connection (SSL encryption). To en-
sure data security, study data will be saved by daily
backups of the study database. In addition, the availabil-
ity of the study server is guaranteed by using the profes-
sional server environment at the IT center of the Charité
University Medicine Berlin. To ensure the quality of the
study data, the monitor performs data control during
the study period. The originals of all central study docu-
ments including documentation forms are kept in the
study coordination office (with the lead investigator) for
at least ten years after completion of the study. The
participating study centers keep the incurred administra-
tive documents (correspondence with ethics committee,
study management, study center), patient identification
list, the signed consent forms, copies of the documen-
tation forms, and the general study documentation
(protocol, Amendments) for the above period. The ori-
ginal data of the study patients (medical records) are
kept according to the filing deadline applicable to the
study sites, but for no less than ten years.
Monitoring
The coordination and implementation of the monitoring
is performed by the Clinical Trial Center Würzburg
(CTCW) at the University Hospital of Würzburg and
the Surgical Regional Center (CRZ) Berlin. Here, the
compliance with the requirements of the study protocol
and ICH/GCP Guidelines are reviewed by the monitors.
Each center is visited once before randomization of the
first patient (initiation visit). Monitor visits are carried
out at appropriate intervals during the study and at
study completion. The verification of the correct transmis-
sion of data in the medical record into the documentation
sheets (100 % Source Data Verification) is performed for
the first two patients enrolled in each study center. The
monitoring of the core data is performed for every patient.
The following is considered as core data: existence of the
patient, patient consent, correct inclusion and exclusion
criteria, primary outcomes, and serious adverse events
according to the protocol.
Assessment of safety, analysis and reporting
Adverse events (AEs) have been defined as pneumonia,
pleural effusion, postoperative bleeding requiring revi-
sion, blood loss requiring transfusion, pleural empyema,
persistent lung fistula that last longer than five days after
surgery, deep vein thrombosis, and wound infection. Ser-
ious adverse events (SAEs) are medical occurrences that
lead to any of the following: immediately life-threatening
situation, re-operation, persistent or significant disabil-
ity/incapacity, inpatient hospitalization or prolongation
of existing hospitalization, admission to an intensive care
unit, death. All SAEs and all adverse events AEs are
documented and assessed by the investigator and docu-
mented in the medical record and in the eCRF, regard-
less of whether, in the opinion of the investigator, there
is a causal relationship with the study conduct or not.
The documentation includes the type of event, start,
end, expression/severity, causality, and outcome of the
incident. Furthermore, the investigator must inform the
lead investigator about the occurrence of an SAE within
three days after having taking note of it and provide the
investigator with a detailed written report (SAE sheet).
Fatal or life-threatening SAEs will promptly, meaning
within 24 hours, be reported after they are known.
Data Safety Monitoring Board (DSMB)
An independent data protection committee (DSMB),
which consists of three external experts (thoracic surgeon,
biometrician, clinical scientist), will be concerned with
patient safety and evaluation of benefits and risks. The
DSMB examines the data collected and monitors patient
safety by evaluation of AEs and SAEs. On the basis of the
evaluated data, the DSMB makes recommendations on
continuation, modification, or termination of the trial.
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The DSMB will meet regularly, at least five times during
the duration of the study.
Dropout/exclusions
The termination criteria of the study are defined as thor-
acic reintervention (for example, drainage system, thora-
centesis with suction, surgery due to recurrence or other
indication), the patient’s desire to withdraw from the
current study, and violation of the protocol. During the
hospital stay after surgery (and thus after randomization)
a new or additional chest tube is not a termination criter-
ion. Also, a pleural puncture for aspiration of pneumo-
thorax or residual pneumothorax is not a termination
criterion. Reoperation during the hospital stay after the
initial procedure with the need for a parenchymal resec-
tion (for example, due to a recurrence pneumothorax or
fistula formation) will cause the exclusion of the patient
from the study. Patients may cancel their participation in
the study at any time they wish, without giving reasons for
the decision. In addition, the principal investigator may
exclude a patient from the study if the continuation of the
study compromises the patient’s well-being. The study
cancellation will be documented in the eCRF and in the
patient’s file, and all SAEs occurring from this point must
be followed up. Premature discontinuation of the entire
study will be done at the recommendation of the DSMB
that the study be terminated for security reasons.
Discussion
Here we report the design of a thoracic surgical multi-
center study WOPP trial which compares two surgical
procedures for the treatment of recurrent pPTX. Both
surgical procedures, the partial apical pleurectomy alone
(PP) and the partial apical pleurectomy in combination
with an additional apical wedge resection (WRPP), are
considered to be safe and well established in specialized
thoracic surgery services worldwide [5, 7, 8]. The aim of
this study is to evaluate whether parietal pleurectomy in
combinination with apical wedge resection is superior
compared to parietal pleurectomy alone in surgical treat-
ment of pPTX. There is no prospective randomized study
on this subject so far. Czerny et al. [7] reported a retro-
spective analysis of 113 patients, 45.2 % receiving partial
pleurectomy (PP) and 54.8 % a partial pleurectomy with
apical wedge resection (WRPP) with recurrence rates after
PP of 7 % and after WRPP of 0 % (p = 0.009). The observa-
tion period was a mean of 38.7 months.
Although guidelines for the treatment of primary spon-
taneous pneumothorax exist, in daily clinical routine a
variety of treatment methods are being used [9–14].
According to a recent AWMF guideline [15], indications
for surgical intervention of pneumothorax are: first event
with radiologically or thoracoscopically recognizable bul-
lae, first recurrence after chest tube treatment, bilateral
synchronous pneumothorax, tension pneumothorax, or
hemopneumothorax. Video-assisted thoracoscopic surgery
(VATS), if necessary thoracotomy, complete inspection of
the lungs, closure of the leakage site or removal of the
bubble-bearing areas of the lung, and a partial parietal
pleurectomy or pleurodesis are recommended. While
specialized thoracic centers rather focus on the guidelines,
the majority of hospitals mostly perform partial pleurect-
omy alone [4, 5]. Finally, economic factors play an inde-
pendent role, so that often the less expensive method is
preferred [16]. Our multicenter study intends to evaluate
the long-term results (recurrence rate over two years),
perioperative morbidity and mortality, postoperative con-
valescence, and postoperative quality of life. Additionally,
data will be collected that allow conclusions on the treat-
ment costs of both surgical procedures. For data analysis a
consultant health economist will be hired.
Trial status
Adequate financial resources are available to cover ap-
propriate personnel (study nurses, project coordinators,
monitors, data managers) and additional expenses. The
study protocol was approved by the Ethics Committee of
the Medical Faculty of the University of Würzburg. The
WOPP trial has been registered since 06.05.2013 on
http://clinicaltrials.gov/ and can be identified worldwide
by the assigned identification number NCT01855464.
All 20 participating study centers have received a study
synopsis and signed the commitment letter (“Declaration
of Commitment”). The currently (as of 07.01.2015) par-
ticipating study centers are (see Table 2): Vivantes Clinic
Neukölln (Berlin), DRK Clinic Berlin-Mitte, Protestant
Lung Clinic Berlin, Charité Campus Mitte, University
Hospital Erlangen, University Hospital Freiburg, Lung
Clinic Großhansdorf, University Hospital Hamburg-
Eppendorf, Thorax Clinic at the University Hospital
Heidelberg, St. Bernward Hospital Hildesheim, Lung
Clinic Cologne-Merheim, Clinic Lowenstein, University
of Munich, Asklepios Clinic Munich-Gauting, Thorax
Center district of Unterfranken, Hospital Barmherzige
Brüder Regensburg, University Hospital Regensburg,
Robert Bosch Hospital in Gerlingen, University Hospital
of Tübingen, and the University Hospital of Würzburg.
Based on the declaration of commitment of all centers,
more than 500 patients should be included in a period
of 24 months in the study. Each study center plans to
recruit annually between 8 and 20 patients. University
and non-university hospitals will take part in the study
to increase the generalizability of the study results. All
participating centers are familiar with the conduct of
clinical trials. Four of the study sites belong to the
national CHIR-Net network of surgical regional study
centers, which are experienced in prospective random-
ized multicenter trials. The final study protocol was
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submitted to all the centers. The first version of the elec-
tronic Case Report Form (eCRF) and the randomization
tool exist. Recruitment was started in October 2013.
Currently (as of 22.01.2015), there are 61 patients ran-
domized. The end of recruitment is planned for October
2015 (“last-patient-in”), and the last study visit will be
carried out until November 2017.
Good clinical practice
The procedures that are defined in the study protocol,
which relate to the implementation, evaluation, and
documentation of the study, are designed to ensure that
all persons who are involved in the study correspond to
good clinical practice and the ethical principles described
in the Declaration of Helsinki. The study will be con-
ducted in accordance with local legal and regulatory
requirements [17–19].
Trial status
Electronic Case Report Forms have been created. Pa-
tient recruitment started in September 2013 with the
centrally organized initiation meeting on 17.09.2013 in
Berlin. Enrollment of the First Patient In was on
19.11.2013.
Additional file
Additional file 1: List of participating centers and ethical bodies.
(DOCX 5 kb)
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